Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.05-7.89%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 34.44% | -43.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 34.44% | -43.62% | |||
| Cost of Revenue | 149.04% | -70.63% | |||
| Gross Profit | 2.38% | -24.10% | |||
| SG&A Expenses | 3.27% | 7.74% | |||
| Depreciation & Amortization | 2.71% | 15.10% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.19% | -11.38% | |||
| Operating Income | -3.65% | -34.81% | |||
| Income Before Tax | -11.46% | -28.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.46% | -28.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 15.00% | -- | |||
| Net Income | -11.43% | -27.67% | |||
| EBIT | -3.65% | -34.81% | |||
| EBITDA | -3.72% | -36.55% | |||
| EPS Basic | 5.41% | -12.67% | |||
| Normalized Basic EPS | 5.42% | -12.09% | |||
| EPS Diluted | 5.41% | -12.67% | |||
| Normalized Diluted EPS | 5.42% | -12.09% | |||
| Average Basic Shares Outstanding | 17.79% | 13.31% | |||
| Average Diluted Shares Outstanding | 17.79% | 13.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||